Researchers from Danish biotech company Exiqon have developed a blood test for colon cancer that could be used as an initial screening tool prior to colonoscopy.
The test works by measuring the levels of microRNAs, tiny bits of genetic material of tumours in the blood.
A study conducted by the researchers which involved healthy donors and people with early stage colorectal cancer showed that the test was able to identify and rule out colon cancer.
The company plans to conduct a large clinical trial involving patients who are due to have a colonoscopy and those who have colon cancer symptoms.
The company is currently in the first year of its four-year project to develop the colonoscopy test.